PEMGARDA (Pemivibart)

PEMGARDA (Pemivibart)

PEMGARDA (Pemivibart) is an FDA-approved monoclonal antibody infusion therapy indicated for the treatment of relapsed or refractory multiple myeloma in adult patients. Each pack contains 9×4 mL single-dose, preservative-free vials of Pemivibart, designed for intravenous administration under professional supervision.

Pemivibart works by targeting specific pathways involved in cancer cell growth and survival, helping to slow disease progression, reduce tumor burden, and improve overall patient outcomes. This therapy is part of a precision oncology approach, offering advanced care for patients who have exhausted other treatment options.

InfusionMed USA, headquartered in Carrollton, Texas, supplies PEMGARDA and other oncology infusion therapies to hospitals, cancer centers, and specialty infusion clinics across Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas regions. We ensure cold-chain compliance, safe handling, and timely delivery for healthcare providers.

For professional use in oncology treatment centers. Administer per prescribing guidelines.

Download Form